F-fluorocholine (FCH) positron emission tomography (PET)/ CT for the detection of hyperfunctioning parathyroid glands in the setting of primary hyperparathyroidism (HPT1) seems promising [1, 2] . Its interest in the surgical management of these diseases has also been reported [3] .
right). Pathological findings after parathyroid surgery revealed adenomas in two parathyroid glands and hyperplasia in another one. The remaining one, measured at 6 mm on FCH-PET/ CT, was left in place. After surgery, the patient had hypoparathyroidism with a calcium level of 2.11 mM (normal range 2.25 to 2.6 mM) and serum parathyroid hormone level of 0.56 pM (normal range 0.48 to 4.2 pM). Cabergoline was initiated to treat prolactinoma.
In MEN1 patients, the estimated penetrances of HPT1 and prolactinoma by the age of 40 are, respectively,~90% and~20% [4] . Incidental detection of pituitary adenoma by FCH-PET/ CT was recently reported but not in a MEN1 patient or for prolactinoma [5] [6] [7] . In our case, the prolactinoma presented an intense FCH focus of uptake compared with what is usually reported as physiologic [8] , but MIBI scintigraphy did not reveal anything. Proton magnetic resonance spectroscopy studies have found that the concentration of choline-containing compounds was significantly higher in pituitary adenomas [9, 10] . MIBI avidity by tissues is related to the number of mitochondria per cell [11] . Presumably, this would explain why in our case, the prolactinonoma was positive on FCH PET/CT and negative on MIBI scintigraphy. Pituitary adenomas with an increased focus of uptake of fluorodeoxyglucose [7] or tetraazacyclododecanetetraacetic acid-Tyr3-octreotide [12] on PET/CTs have already been reported, but these radiotracers are not relevant to explore parathyroid glands.
FCH-PET/CT needs to be evaluated in a larger number of patients with MEN1. Indeed, it could help to detect more hyperfunctioning parathyroid glands than other imaging modalities and identify other potential endocrine tumors as well.
